Skip to main content
PMC home page
Journal of Clinical and Experimental Hepatology logoLink to Journal of Clinical and Experimental Hepatology
. 2012 Jan 2;1(3):185–189. doi: 10.1016/S0973-6883(11)60130-8

Occult Hepatitis C Virus Infection and Its Relevance in Clinical Practice

Tram NQ Pham 1, Tomasz I Michalak 1,*
PMCID: PMC3940301  PMID: 25755384

Abstract

Hepatitis C virus (HCV) can persist in the liver, lymphoid (immune) cells, and serum of individuals long after an apparently complete therapy-induced or a spontaneous resolution of hepatitis C. This essential asymptomatic infection, called secondary occult HCV infection (OCI), usually occurs in anti-HCV antibody reactive individuals with normal liver function tests. This infection has been identified when the nucleic acid amplification assays of enhanced sensitivity were applied for the detection of HCV genome and its replication. In addition to the secondary OCI, a form of low-level HCV-RNA-positive infection of unknown etiology coinciding with moderately elevated serum liver enzymes and progressing in the absence of anti-HCV detectable by standard clinical assays has been reported. Because of its undefined origin, it can be termed cryptogenic OCI. In this review, the general characteristics of OCI, the ways of its detection and associated controversies, and the potential clinical implications of its existence will be concisely outlined.

Keywords: Clinical practice, hepatitis C, identification of OCI, occult HCV infection

Abbreviations: CHC, chronic hepatitis C; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; IFN, interferon; IU, international unit; NAH, nucleic acid hybridization; OCI, occult HCV infection; PBMC, peripheral blood mononuclear cells; PCR, polymerase chain reaction; RBV, ribavirin; RNA, ribonucleic acid; SVR, sustained virological response

Full Text

The Full Text of this article is available as a PDF (104.8 KB).

References

  • 1.Alberti A, Chemello L, Benvegnu L. Natural history of hepatitis C. J Hepatol. 1999;31:17–24. doi: 10.1016/s0168-8278(99)80369-9. [DOI] [PubMed] [Google Scholar]
  • 2.Blackard JT, Kemmer N, Sherman KE. Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences. Hepatology. 2006;44:15–22. doi: 10.1002/hep.21283. [DOI] [PubMed] [Google Scholar]
  • 3.Lerat H, Rumin S, Habersetzer F. In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load, viral genotype, and cell phenotype. Blood. 1998;91:3841–3849. [PubMed] [Google Scholar]
  • 4.Pal S, Sullivan DG, Kim S. Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: implications of HCV lymphotropism. Gastroenterology. 2006;130:1107–1116. doi: 10.1053/j.gastro.2005.12.039. [DOI] [PubMed] [Google Scholar]
  • 5.Pham TN, King D, MacParland SA. Hepatitis C virus replicates in the same immune cell subsets in chronic hepatitis C and occult infection. Gastroenterology. 2008;134:812–822. doi: 10.1053/j.gastro.2007.12.011. [DOI] [PubMed] [Google Scholar]
  • 6.Zignego AL, Macchia D, Monti M. Infection of peripheral mononuclear blood cells by hepatitis C virus. J Hepatol. 1992;15:382–386. doi: 10.1016/0168-8278(92)90073-x. [DOI] [PubMed] [Google Scholar]
  • 7.MacParland SA, Pham TN, Gujar SA, Michalak TI. De novo infection and propagation of wild-type Hepatitis C virus in human T lymphocytes in vitro. J Gen Virol. 2006;87:3577–3586. doi: 10.1099/vir.0.81868-0. [DOI] [PubMed] [Google Scholar]
  • 8.MacParland SA, Pham TN, Guy CS, Michalak TI. Hepatitis C virus persisting after clinically apparent sustained virological response to antiviral therapy retains infectivity in vitro. Hepatology. 2009;49:1431–1441. doi: 10.1002/hep.22802. [DOI] [PubMed] [Google Scholar]
  • 9.Kondo Y, Sung VM, Machida K, Liu M, Lai MM. Hepatitis C virus infects T cells and affects interferon-gamma signaling in T cell lines. Virology. 2007;361:161–173. doi: 10.1016/j.virol.2006.11.009. [DOI] [PubMed] [Google Scholar]
  • 10.Morsica G, Tambussi G, Sitia G. Replication of hepatitis C virus in B lymphocytes (CD19+) Blood. 1999;94:1138–1139. [PubMed] [Google Scholar]
  • 11.Castillo I, Rodriguez-Inigo E, Lopez-Alcorocho JM, Pardo M, Bartolome J, Carreno V. Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment. Clin Infect Dis. 2006;43:1277–1283. doi: 10.1086/508198. [DOI] [PubMed] [Google Scholar]
  • 12.Ciancio A, Smedile A, Giordanino C. Long-term follow-up of previous hepatitis C virus positive nonresponders to interferon monotherapy successfully retreated with combination therapy: are they really cured? Am J Gastroenterol. 2006;101:1811–1816. doi: 10.1111/j.1572-0241.2006.00669.x. [DOI] [PubMed] [Google Scholar]
  • 13.Pham TN, MacParland SA, Mulrooney PM, Cooksley H, Naoumov NV, Michalak TI. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol. 2004;78:5867–5874. doi: 10.1128/JVI.78.11.5867-5874.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Radkowski M, Gallegos-Orozco JF, Jablonska J. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology. 2005;41:106–114. doi: 10.1002/hep.20518. [DOI] [PubMed] [Google Scholar]
  • 15.Castillo I, Pardo M, Bartolome J. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis. 2004;189:7–14. doi: 10.1086/380202. [DOI] [PubMed] [Google Scholar]
  • 16.George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology. 2009;49:729–738. doi: 10.1002/hep.22694. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Maylin S, Martinot-Peignoux M, Ripault MP. Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody. Liver Int. 2009;29:511–517. doi: 10.1111/j.1478-3231.2008.01918.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Nicot F, Kamar N, Mariame B, Rostaing L, Pasquier C, Izopet J. No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients. Transpl Int. 2010;23:594–601. doi: 10.1111/j.1432-2277.2009.01025.x. [DOI] [PubMed] [Google Scholar]
  • 19.Halfon P, Bourliere M, Ouzan D. Occult hepatitis C virus infection revisited with ultrasensitive real-time PCR assay. J Clin Microbiol. 2008;46:2106–2108. doi: 10.1128/JCM.00345-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Bokharaei-Salim F, Keyvani H, Monavari SH. Occult hepatitis C virus infection in Iranian patients with cryptogenic liver disease. J Med Virol. 2011;83:989–995. doi: 10.1002/jmv.22044. [DOI] [PubMed] [Google Scholar]
  • 21.Zaghloul H, El Sherbiny W. Detection of occult hepatitis C and hepatitis B virus infections from peripheral blood mononuclear cells. Immunol Invest. 2010;39:284–291. doi: 10.3109/08820131003605820. [DOI] [PubMed] [Google Scholar]
  • 22.Pham TN, Coffin CS, Michalak TI. Occult hepatitis C virus infection: what does it mean? Liver Int. 2010;30:502–511. doi: 10.1111/j.1478-3231.2009.02193.x. [DOI] [PubMed] [Google Scholar]
  • 23.Pham TN, Coffin CS, Churchill ND, Urbanski SJ, Lee SS, Michalak TI. Hepatitis C virus persistence after sustained virological response to antiviral therapy in patients with or without past exposure to hepatitis B virus. J Viral Hepat. 2011 doi: 10.1111/j.1365-2893.2011.01442.x. (published online March 1, 2011). [DOI] [PubMed] [Google Scholar]
  • 24.Pham TN, MacParland SA, Coffin CS, Lee SS, Bursey FR, Michalak TI. Mitogen-induced upregulation of hepatitis C virus expression in human lymphoid cells. J Gen Virol. 2005;86:657–666. doi: 10.1099/vir.0.80624-0. [DOI] [PubMed] [Google Scholar]
  • 25.Di Liberto G, Roque-Afonso AM, Kara R. Clinical and therapeutic implications of hepatitis C virus compartmentalization. Gastroenterology. 2006;131:76–84. doi: 10.1053/j.gastro.2006.04.016. [DOI] [PubMed] [Google Scholar]
  • 26.Ducoulombier D, Roque-Afonso AM, Di Liberto G. Frequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes. Hepatology. 2004;39:817–825. doi: 10.1002/hep.20087. [DOI] [PubMed] [Google Scholar]
  • 27.Coppola N, Pisaturo M, Guastafierro S. Absence of occult HCV infection in patients under immunosuppressive therapy for oncohematological diseases. Hepatology. 2011;54:1487–1489. doi: 10.1002/hep.24436. [DOI] [PubMed] [Google Scholar]
  • 28.Castillo I, Bartolome J, Quiroga JA, Barril G, Carreno V. Presence of HCV-RNA after ultracentrifugation of serum samples during the follow-up of chronic hepatitis C patients with a sustained virological response may predict reactivation of hepatitis C virus infection. Aliment Pharmacol Ther. 2009;30:477–486. doi: 10.1111/j.1365-2036.2009.04066.x. [DOI] [PubMed] [Google Scholar]
  • 29.Germer JJ, Zein NN. Advances in the molecular diagnosis of hepatitis C and their clinical implications. Mayo Clin Proc. 2001;76:911–920. doi: 10.4065/76.9.911. [DOI] [PubMed] [Google Scholar]
  • 30.Formann E, Steindl-Munda P, Hofer H. Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy. Aliment Pharmacol Ther. 2006;23:507–511. doi: 10.1111/j.1365-2036.2006.02785.x. [DOI] [PubMed] [Google Scholar]
  • 31.Berasain C, Betes M, Panizo A. Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology. Gut. 2000;47:429–435. doi: 10.1136/gut.47.3.429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Hoare M, Gelson WT, Rushbrook SM. Histological changes in HCV antibody-positive, HCV RNA-negative subjects suggest persistent virus infection. Hepatology. 2008;48:1737–1745. doi: 10.1002/hep.22484. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Charlton M, Seaberg E, Wiesner R. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology. 1998;28:823–830. doi: 10.1002/hep.510280333. [DOI] [PubMed] [Google Scholar]
  • 34.Lee WM, Poison JE, Carney DS, Sahin B, Gale M., Jr Reemergence of hepatitis C virus after 8.5 years in a patient with hypogammaglobulinemia: evidence for an occult viral reservoir. J Infect Dis. 2005;192:1088–1092. doi: 10.1086/432917. [DOI] [PubMed] [Google Scholar]
  • 35.Lin A, Thadareddy A, Goldstein MJ, Lake-Bakaar G. Immune suppression leading to hepatitis C virus re-emergence after sustained virological response. J Med Virol. 2008;80:1720–1722. doi: 10.1002/jmv.21257. [DOI] [PubMed] [Google Scholar]
  • 36.Nudo CG, Cortes RA, Weppler D, Schiff ER, Tzakis AG, Regev A. Effect of pretransplant hepatitis C virus RNA status on posttransplant outcome. Transplant Proc. 2008;40:1449–1455. doi: 10.1016/j.transproceed.2008.03.158. [DOI] [PubMed] [Google Scholar]
  • 37.Thomopoulos K, Giannakoulas NC, Tsamandas AC. Recurrence of HCV infection in a sustained responder after chemotherapy for non-Hodgkin's lymphoma: successful retreatment. Am J Med Sci. 2008;336:73–76. doi: 10.1097/MAJ.0b013e318159d1a8. [DOI] [PubMed] [Google Scholar]
  • 38.Kobayashi S, Takeda T, Enomoto M. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. Liver Int. 2007;27:186–191. doi: 10.1111/j.1478-3231.2006.01406.x. [DOI] [PubMed] [Google Scholar]
  • 39.Makiyama A, Itoh Y, Kasahara A. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer. 2004;101:1616–1622. doi: 10.1002/cncr.20537. [DOI] [PubMed] [Google Scholar]
  • 40.Veldt BJ, Saracco G, Boyer N. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut. 2004;53:1504–1508. doi: 10.1136/gut.2003.038257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Veldt BJ, Heathcote EJ, Wedemeyer H. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677–684. doi: 10.7326/0003-4819-147-10-200711200-00003. [DOI] [PubMed] [Google Scholar]
  • 42.Freeman AJ, Dore GJ, Law MG. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology. 2001;34:809–816. doi: 10.1053/jhep.2001.27831. [DOI] [PubMed] [Google Scholar]
  • 43.Casato M, Lilli D, Donato G. Occult hepatitis C virus infection in type II mixed cryoglobulinaemia. J Viral Hepat. 2003;10:455–459. doi: 10.1046/j.1365-2893.2003.00462.x. [DOI] [PubMed] [Google Scholar]
  • 44.Pardo M, Castillo I, Arenas MD. Antiviral therapy in patients with occult HCV infection. Hepatology. 2005;42:658A. [Google Scholar]
  • 45.Raimondo G, Allain JP, Brunetto MR. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008;49:652–657. doi: 10.1016/j.jhep.2008.07.014. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical and Experimental Hepatology are provided here courtesy of Elsevier

RESOURCES